Edmond de Rothschild Private Equity
The Edmond de Rothschild Group is a leader in private equity.
Business Model:
Revenue: $404.5M
Employees: 1,001-5,000
Rankings
Detailed Edmond de Rothschild Private Equity Information
Geographic Data
Address: 18 rue de Hesse
City: Suisse
State: geneva
Zip: 1204
Country: CH
Financial Info
Stage:
Raised Last:
$0
Raised Total:$1B
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
1,779,279Website Global Rank
15,044Website Monthly Traffic
Twitter Followers
Description
The Edmond de Rothschild Group is a leader in private equity, using its family experience to assist companies. Their teams are not merely financial investors. They are active partners in company growth and work closely with company executives on value creation. Their Group has long understood that taking environmental, social and governance (ESG) issues into consideration is key to both risk management and value creation for all of the companies in its portfolio. Each area of expertise applies considerations from outside the realm of finance to its specific investment strategy and implements the highest ESG standards.
Contact Phone:
+14158819111
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2022 | Française de l&s;Energie | Post-IPO Debt | 19.7M |
| 9/2021 | Française de l&s;Energie | Post-IPO Debt | 46.8M |
| 4/2019 | Swiss Summit Capital | Series A | 0 |
| 2/2011 | Sergeant Major | Private Equity Round | 43.4M |
| 12/2022 | North Star | Debt Financing | 169.9M |
| 10/2017 | Philogeris Group | Venture Round | - |
| 6/2016 | Allecra Therapeutics | Series B | 24.8M |
| 1/2017 | Avalyn Pharma | Series A | 0 |
| 4/2013 | Allecra Therapeutics | Series A | 19.6M |
| 3/2008 | PanGenetics | Series C | 35.1M |
| 3/2009 | GlycoVaxyn | Series B | 21.4M |
| 1/2015 | Genkyotex | Post-IPO Equity | 0 |
| 12/2013 | Covagen | Series B | 0 |
| 8/2013 | OncoEthix | Series B | 0 |
| 10/2022 | Française de l&s;Energie | Post-IPO Debt | 0 |
| 9/2021 | Française de l&s;Energie | Post-IPO Debt | 0 |
| 4/2019 | Swiss Summit Capital | Series A | 0 |
| 10/2017 | Philogeris Group | Venture Round | - |
| 1/2017 | Avalyn Pharma | Series A | 0 |
| 6/2016 | Allecra Therapeutics | Series B | 0 |
| 1/2015 | Genkyotex | Post-IPO Equity | 0 |
| 12/2013 | Covagen | Series B | 0 |
| 8/2013 | OncoEthix | Series B | 0 |
| 4/2013 | Allecra Therapeutics | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
